



Urinary Tract Infection in Egyptian Renal Transplant Recipients

Thesis

*Submitted for Partial Fulfillment of
Master degree in Internal Medicine*

Presented By

Mohamad Saeed Hassan

M.B. B.ch.

Faculty of Medicine- Ain Shams University

Under Supervision of

Prof. Dr. Essam Mohamed Soliman Khedr

*Professor of Internal Medicine & Nephrology
Faculty of Medicine - Ain Shams University*

Dr. Aber Halim Baki

*Lecturer of Internal Medicine & Nephrology
Faculty of Medicine - Ain Shams University*

Faculty of Medicine

Ain Shams University

2010

Acknowledgment

*The following thesis, benefited from the insights and direction of several people . First, my Thesis Chair, **Prof .Dr . Essam Khedr**, provided timely and instructive comments and evaluation at every stage of the thesis process, allowing me to complete this project on schedule. Also, **Dr. Aber Halim** for his support and instructions.*

*Also, I'd like to thank **Prof. Dr. Yahia Elshazly** and **Prof. Dr. Mohamed Hani Hafez** for their attendance and participation in the discussion of my thesis .*

Table of contents

Section	Title		Page
	List of abbreviations		III
	List of Tables		VII
	List of Figures		XI
I	Introduction and Aim of the study		1
II	Review of the Literature		
	<i>Chapter 1</i>	<i>INFECTIOUS COMPLICATIONS IN RENAL TRANSPLANT RECIEPIENTS</i>	11
	<i>Chapter 2</i>	<i>UTI IN RENAL TRANSPLANT RECIPIENTS "AN OVERVIEW"</i>	36
	<i>Chapter 3</i>	<i>PATHOGENESIS AND RISK FACTORS OF UTI IN RENAL TRANSPLANT RECIPIENTS</i>	45
	<i>Chapter 4</i>	<i>CLINICAL PICTURE AND INVESTIGATIONS OF UTI IN RENAL TRANSPLANT RECIPIENTS</i>	74
	<i>Chapter 5</i>	<i>COMPLICATIONS AND MANAGEMENT OF UTI IN RENAL TRANSPLANT RECIPIENTS</i>	86

Section	Title	Page
III	Patients and Methods	109
IV	Results and statistics	114
V	Discussion	135
VI	Summary and Conclusion	146
VII	Recommendations	152
VIII	References	155

List of abbreviations

99 mTc-DMSA SPECT	Technetium 99 _m 2,3 dimercapto-succinic acid single-photon emission computer tomography
AAI	Acute allograft injury
ADPKD	Autosomal Dominant Polycystic Kidney Disease
APN	Acute pyelonephritis
ATG	Antithymocyte globulins
AZA	Azathioprine
BK	Balkan virus
C.difficile	Clostridium difficile
CD	Clusters of differentiation
CFU	Colony forming unit
Ch	Chronic
CMV	Cytomegalovirus
CS	Corticosteroid
CsA	Cyclosporine
CT	Computed tomography
DAF	Decay accelerating factor
DD	Deceased donor
DGF	Delayed graft function
dl	Deciliter
DM	Diabetes mellitus
DMSA	Dimercaptosuccinic acid
E.Coli	Escherichia coli

List of abbreviations

EBV	Epstein barr virus
ESRD	End stage renal disease
Ever	Everolimus
GFR	Glomerular filtration rate
GN	Glomerlonephritis
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HD	Haemodialysis
HIV	Human immune deficiency virus
HPF	High power field
HSV	Herpes simplex virus
HTLV	Human T cell lymphotropic virus
HTN	Hypertension
IgA	Immunoglobulin A
IL	Interleukin
Interst nephr	Interstitial nephritis
LD	Living donor
LPS	Lipopolysaccharide
MCUG	Micturating cystourethrogram
MDRD	Modification of Diet in Renal Disease
Mg/l	Milligram/liter
ML	Milliliter
MMF	Mycophenolate mofetil

List of abbreviations

mRNA	Messenger ribonucleic acid
MRSA	Methicilline resistant staphylococcus aureus
Ms	Months
Obst urop	Obstructive uropathy
OKT 3	Brand name for muromonab-CD3
Pap	Pyelonephritis-associated pili
PCP	Pneumocystitis carini pneumonia
PET	Positron emission tomography
PKD	Polycystic kidney disease
PTLD	Post transplantation lymphoproliferative disorder
Pyeloneph	Pyelonephritis
RSV	Respiratory syncitial virus
S stercoralis	Strongyloides stercoralis
S.saprophyticus	Staphylococcus saprophyticus
SARS	Severe acute respiratory syndrome
Sig	Significance
sIL-RA	Soluble interleukin receptor antagonist
SRL	Sirolimus
Staph	Staphylococcus
Std.deviation	Standard deviation
Strept	Streptococcus
T cruzi	Trypenosoma cruzi

List of abbreviations

T gondii	Toxoplasma gondii
TAC	Tacrolimus
TB	Tuberculosis
TMP-SMZ	Trimethoprim-sulphamethaxazole
TNF	Tumour necrosis factor
Tx	Transplant
USRDS	United States Renal Data System
UTI	Urinary tract infection
VRE	Vancomycin resistant enterococci
VUR	Vesico ureteric reflux
VZV	Varicella zoster virus
WBC	White blood cells
Ys	Years

List of Tables:

Table	Title	Page
1	Some descriptive Data about the patients included in the study.	114
2	Prevalence of pyuria, post TX UTI in the study.	115
3	Comparison between preemptive group and non preemptive group as regard prevalence of post transplant UTI.	116
4	Comparison between some quantitative variables in both groups using the independent Sample t test.	117
5	Comparison between positive and negative group as regard sex.	118
6	Etiology of ESRD in relation to post TX UTI.	119
7	Effect of multiple etiologies on prevalence of UTI.	121

Table	Title	Page
8	Comparison between positive and negative groups as regard presence of bilharziasis and reflux.	121
9	Comparison of HCV positive and HCV negative recipients as regard presence of post TX UTI.	122
10	Causative organisms of UTI in the study.	122
11	Effect of induction therapy on occurrence of post TX UTI.	124
12	Immunosuppressive protocols and relation to UTI.	124
13	Comparison between positive group and negative group as regard acute rejection episodes.	125
14	Comparison between prevalence of post transplant UTI in patients with pre transplant UTI and without pre transplant UTI.	125

Table	Title	Page
15	Comparison between prevalence of UTI in patients with surgical complication and patients without surgical complication.	126
16	Native kidney nephrectomy, its timing, and relation to post TX UTI.	127
17	Unilateral or bilateral nephrectomy in relation to UTI.	127
18	Comparison between first and second transplant recipients as regard prevalence of UTI.	128
19	Comparison between positive group and negative group as regard presence of CMV infection.	128
20	Rise of creatinine during UTI episodes.	129
21	Comparison between Both groups as regard GFR, level of creatinine during episodes of UTI and last serum creatinine.	129

Table	Title	Page
22	Comparison of overall graft survival in both positive and negative groups.	131
23	Comparison between 5 year graft survival in both positive and negative groups.	131
24	Comparison of risk estimation of graft loss between both groups.	132
25	Value of significance of Survival test (Mantel COX).	132

List of Figures:

Figure	Title	Page
1	The timeline of infection after transplantation.	24
2	Prevalence of pyuria, post TX UTI in the study.	115
3	Etiology of ESRD among the 300 recipients.	120
4	Etiology of ESRD among positive group.	120
5	Causatives organisms of UTI in the study.	123
6	Comparison between GFR in both groups.	130
7	5 year graft survival in both groups.	132

INTRODUCTION

Kidney transplantation is the best available replacement therapy for patients with end-stage renal disease (ESRD) (*Veroux M et al., 2008*).

Successful renal transplantation allows freedom from the lifestyle restrictions and complications associated with dialysis and are therefore associated with better quality of life. One study of United States Renal Data System (USRDS) data compared outcomes in patients on the transplant waiting list (ie, who were continuing to receive dialysis) with those of controls who had received a kidney transplant. It found that, after 3 to 4 years of follow-up, transplantation reduced the risk of death overall by 68%. Transplantation conferred a survival benefit in almost all subgroups, including in elderly or obese patients or those with hepatitis C. In addition, over the long term, it is more cost-efficient than dialysis. Thus, transplantation remains the optimal therapy for patients with end-stage renal disease (ESRD) (*Magee CC&Pascual M, 2004*).

Despite improved outcomes in kidney transplant patients over the years, infectious complications remain a significant cause of morbidity and mortality in this population (*Witzke O et al, 2001*).

Infectious complications are the second most common cause of death after transplantation, Urinary tract infection (UTI) is the most common infectious complication following renal transplantation (*Senger SS et al, 2007*).

The first month post–kidney transplantation is considered the critical time, with most UTI episodes during this period., Beyond three months after transplantation, the incidence of UTI decreases progressively (*Khosroshahi HT et al, 2006*).

The major risk factors for UTI in the renal transplant recipient include pre-transplantation UTI, prolonged period of HD, polycystic kidney disease, DM, shistomiasis, immuno-suppression, allograft trauma, and technical complications associated with ureteral anastomosis, prolonged postoperative bladder catheterization , Female recipients had significantly more UTI than males (*De Souza RM& Olsburgh J, 2008*).

Urinary tract infection (UTI) is commonly due to bacterial infection in the post-transplantation period. Fungi and viruses can also cause UTIs, but infections caused by these organisms are less commonly (*De Souza RM& Olsburgh J, 2008*).

It was found that gram-negative organisms were seen most frequently (73%) in renal transplant recipients hospitalized with urinary tract infections, were Gram-negative bacilli with